Albert Labs, a British-Columbia based biotech company, announced Thursday that it closed its private placement and that its shares will begin trading on the Canadian Securities Exchange (CSE). Albert Labs will trade under the ticker symbol “ABRT.”
“The listing is the first of many major milestones for Albert Labs. We are very excited by the market potential, as the first company pursuing psilocybin Real World Evidence trials in the UK. We believe this will be an attractive and ethical proposition for new and existing investors alike - Which enables Albert Labs to develop novel therapeutics whilst treating patients who are in need,” said Dr Michael Raymont, CEO and chairman of the company.
